Cheng CY, Hao WR, Liu JC, Cheng TH. Teneligliptin mitigates diabetic cardiomyopathy through inflammasome inhibition: Insights from experimental studies. World J Diabetes 2024; 15(12): 2370-2375 [DOI: 10.4239/wjd.v15.i12.2370]
Corresponding Author of This Article
Tzu-Hurng Cheng, PhD, Professor, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91 Xueshi Road, North District, Taichung City 404333, Taiwan. [email protected]
Research Domain of This Article
Medicine, Research & Experimental
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Chun-Yao Cheng, Department of Medical Education, National Taiwan University Hospital, Taipei 100225, Taiwan
Wen-Rui Hao, Ju-Chi Liu, Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Ministry of Health and Welfare, Taipei Medical University, New Taipei City 23561, Taiwan
Wen-Rui Hao, Ju-Chi Liu, Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei City 11002, Taiwan
Tzu-Hurng Cheng, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, Taichung City 404333, Taiwan
Co-first authors: Chun-Yao Cheng and Wen-Rui Hao.
Author contributions: Cheng CY and Hao WR contribute equally to this study as co-first authors; Cheng CY and Hao WR conceptualized the editorial and provided critical insights into the relevance of the study; Liu JC contributed to the analysis and interpretation of the study’s findings; Cheng TH supervised the editorial process and provided overall guidance; all of the authors read and approved the final version of the manuscript to be published.
Conflict-of-interest statement: All authors declare having no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tzu-Hurng Cheng, PhD, Professor, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91 Xueshi Road, North District, Taichung City 404333, Taiwan. [email protected]
Received: March 11, 2024 Revised: September 27, 2024 Accepted: October 29, 2024 Published online: December 15, 2024 Processing time: 251 Days and 4.1 Hours
Abstract
This article provides commentary on the article by Zhang et al. In this original research, Zhang et al investigated the therapeutic potential of teneligliptin for diabetic cardiomyopathy (DCM), which was mediated by targeting the NOD-like receptor protein 3 (NLRP3) inflammasome. Through the use of both in vivo and in vitro models, the study demonstrated that teneligliptin alleviates cardiac hypertrophy, reduces myocardial injury, and mitigates the inflammatory responses associated with DCM. These findings suggest that teneligliptin’s cardioprotective effects are mediated through the inhibition of NLRP3 inflammasome activation, positioning it as a promising therapeutic option for managing DCM in diabetic patients.
Core Tip: Teneligliptin can mitigate diabetic cardiomyopathy (DCM) by inhibiting NOD-like receptor protein 3 inflammasome activation and upregulating AMP-activated protein kinase signaling. This study provides insights into the molecular mechanisms underlying the beneficial effects of teneligliptin for the treatment of DCM.
